全文获取类型
收费全文 | 1437808篇 |
免费 | 121806篇 |
国内免费 | 4003篇 |
专业分类
耳鼻咽喉 | 21977篇 |
儿科学 | 42744篇 |
妇产科学 | 41104篇 |
基础医学 | 190944篇 |
口腔科学 | 45181篇 |
临床医学 | 138073篇 |
内科学 | 287125篇 |
皮肤病学 | 33600篇 |
神经病学 | 117918篇 |
特种医学 | 57144篇 |
外国民族医学 | 440篇 |
外科学 | 226122篇 |
综合类 | 31569篇 |
现状与发展 | 45篇 |
一般理论 | 449篇 |
预防医学 | 105586篇 |
眼科学 | 33910篇 |
药学 | 102441篇 |
4篇 | |
中国医学 | 3202篇 |
肿瘤学 | 84039篇 |
出版年
2018年 | 18835篇 |
2017年 | 16891篇 |
2016年 | 18434篇 |
2015年 | 19823篇 |
2014年 | 26976篇 |
2013年 | 37267篇 |
2012年 | 37583篇 |
2011年 | 39244篇 |
2010年 | 27667篇 |
2009年 | 29058篇 |
2008年 | 37445篇 |
2007年 | 39448篇 |
2006年 | 40972篇 |
2005年 | 38302篇 |
2004年 | 36721篇 |
2003年 | 35331篇 |
2002年 | 34738篇 |
2001年 | 65303篇 |
2000年 | 66390篇 |
1999年 | 56931篇 |
1998年 | 16583篇 |
1997年 | 15216篇 |
1996年 | 14702篇 |
1995年 | 13745篇 |
1994年 | 12445篇 |
1992年 | 43417篇 |
1991年 | 41835篇 |
1990年 | 41001篇 |
1989年 | 40007篇 |
1988年 | 37415篇 |
1987年 | 36727篇 |
1986年 | 35211篇 |
1985年 | 33359篇 |
1984年 | 25054篇 |
1983年 | 21321篇 |
1982年 | 12869篇 |
1981年 | 11737篇 |
1979年 | 23980篇 |
1978年 | 17171篇 |
1977年 | 14937篇 |
1976年 | 13463篇 |
1975年 | 15321篇 |
1974年 | 18146篇 |
1973年 | 17609篇 |
1972年 | 16874篇 |
1971年 | 15751篇 |
1970年 | 14965篇 |
1969年 | 14363篇 |
1968年 | 13460篇 |
1967年 | 12015篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Aaron Pitzele Mohammad Rahimi Eric Armbrecht 《The journal of maternal-fetal & neonatal medicine》2015,28(15):1770-1773
Objective: To determine whether packed red blood cell (PRBC) transfusion affects post-prandial superior mesenteric artery blood flow velocities (SMA BFVs) in very-low birth weight (VLBW) neonates and if so, at what time point after transfusion restoration of previous SMA BFV patterns occurs.Design/Methods: VLBW pre-term neonates, older than 14 days and tolerating bolus enteral feedings administered every 3?h were enrolled in this prospective observational study. Pulsed Doppler ultrasound was used to measure pre- and post-prandial (at 45?min) time-averaged mean, peak and end diastolic velocities (TAMV, PSV, EDV) immediately before and after 15?ml/kg of PRBC transfusion was given over 3?h; patent ductus arteriosus (PDA) status was also evaluated. Subsequent pre- and post-prandial SMA BFVs were recorded 24 and 48?h after the transfusion.Results: Pre- and post-prandial measurements were obtained for 21 out of 25 enrolled infants. Post-prandial SMA BFVs were attenuated during the feedings immediately after transfusion; at 24 and 48?h after transfusion, changes in post-prandial SMA BFVs were similar to those measured prior to transfusion; the presence of the PDA did not affect results.Conclusions: PRBC transfusion blunted SMA BFV responses to feedings immediately after the transfusion with normalization observed 24?h post-transfusion. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
Julia H. Vermylen Gordon J. Wood Elaine R. Cohen Jeffrey H. Barsuk William C. McGaghie Diane B. Wayne 《Journal of pain and symptom management》2019,57(3):682-687
Introduction
Physician communication impacts patient outcomes. However, communication skills, especially around difficult conversations, remain suboptimal, and there is no clear way to determine the validity of entrustment decisions. The aims of this study were to 1) describe the development of a simulation-based mastery learning (SBML) curriculum for breaking bad news (BBN) conversation skills and 2) set a defensible minimum passing standard (MPS) to ensure uniform skill acquisition among learners.Innovation
An SBML BBN curriculum was developed for fourth-year medical students. An assessment tool was created to evaluate the acquisition of skills involved in a BBN conversation. Pilot testing was completed to confirm improvement in skill acquisition and set the MPS.Outcomes
A BBN assessment tool containing a 15-item checklist and six scaled items was developed. Students' checklist performance improved significantly at post-test compared to baseline (mean 65.33%, SD = 12.09% vs mean 88.67%, SD = 9.45%, P < 0.001). Students were also significantly more likely to have at least a score of 4 (on a five-point scale) for the six scaled questions at post-test. The MPS was set at 80%, requiring a score of 12 items on the checklist and at least 4 of 5 for each scaled item. Using the MPS, 30% of students would require additional training after post-testing.Comments
We developed a SBML curriculum with a comprehensive assessment of BBN skills and a defensible competency standard. Future efforts will expand the mastery model to larger cohorts and assess the impact of rigorous education on patient care outcomes. 相似文献10.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.